Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AJU-A51 vs Co-administration of Dapagliflozin and Linagliptin in Healthy Volunteers
NCT04972539Phase 1Completed
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Area Under Curve last and Maximum Plasma Concentration. Started Aug 2020; status: completed.
02
Drugs
dapagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04972539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972539.